CytomX Therapeutics (CTMX) stock price, revenue, and financials

CytomX Therapeutics market cap is $331.7 m, and annual revenue was $59.50 m in FY 2018

$331.7 M

CTMX Mkt cap, 21-Feb-2020

$10.7 M

CytomX Therapeutics Revenue Q3, 2019
CytomX Therapeutics Net income (Q3, 2019)-23.7 M
CytomX Therapeutics EBIT (Q3, 2019)-25.7 M
CytomX Therapeutics Cash, 30-Sept-2019164.6 M
CytomX Therapeutics EV192.6 M

CytomX Therapeutics Balance Sheet

Annual

USDFY, 2015FY, 2016FY, 2017FY, 2018

Cash

59.8m104.6m177.5m247.6m

Accounts Receivable

744.0k2.2m10.1m97.0k

Prepaid Expenses

4.4m9.3m

Inventories

2.3m3.9m

Current Assets

189.8m188.1m388.6m445.5m

PP&E

3.5m4.4m4.2m6.9m

Goodwill

949.0k949.0k949.0k949.0k

Total Assets

197.2m199.1m397.6m457.1m

Accounts Payable

4.7m6.6m4.2m5.1m

Current Liabilities

15.7m35.8m61.1m97.9m

Long-term debt

1.6m

Total Liabilities

120.6m327.7m326.2m

Common Stock

1.0k1.0k

Additional Paid-in Capital

243.7m254.9m289.5m446.0m

Retained Earnings

(117.5m)(176.4m)(219.5m)(315.0m)

Total Equity

126.1m78.5m69.9m130.9m

Financial Leverage

1.6 x2.5 x5.7 x3.5 x

CytomX Therapeutics Cash Flow

Annual

USDFY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(35.4m)(58.9m)(43.1m)(84.6m)

Depreciation and Amortization

1.2m1.7m1.6m1.9m

Accounts Receivable

1.1m(1.8m)(8.0m)10.0m

Accounts Payable

2.9m1.8m(2.4m)261.0k

Cash From Operating Activities

(27.4m)(2.0m)170.4m(75.5m)

Purchases of PP&E

(1.6m)(2.2m)(1.6m)(3.8m)

Cash From Investing Activities

(130.6m)45.9m(121.3m)5.9m

Dividends Paid

Cash From Financing Activities

153.4m996.0k23.8m139.6m

Net Change in Cash

72.9m70.0m

CytomX Therapeutics Ratios

USDY, 2019

EV/EBIT

-7.5 x

EV/CFO

-1.7 x

Financial Leverage

4.5 x

CytomX Therapeutics Operating Metrics

FY, 2016

Patents (Foreign)

4

Patents (US)

13

Patents Pending

144

Phase I Trials Products

1

Preclinical Phase Products

4

CytomX Therapeutics Employee Rating

3.610 votes
Culture & Values
5.0
Work/Life Balance
4.3
Senior Management
4.5
Salary & Benefits
4.6
Career Opportunities
4.5
Source